 |
 |
|
|
RESÚMENES NOVIEMBRE 2006 |
Psychotic Disorders
& Antipsychotics
(Haga un click en la información del journal para acceder al resúmen)
Improvement in
Social Competence With
Short-Term Atypical Antipsychotic Treatment: A Randomized, Double-Blind Comparison of Quetiapine Versus Risperidone for Social Competence, Social Cognition, and Neuropsychological Functioning
Philip D. Harvey, Thomas L. Patterson, Larry S. Potter, Kate Zhong, and Martin Brecher
American
Journal of Psychiatry 163:1918-1925, November 2006
Atypical
antipsychotic monitoring: A survey of patient knowledge and experience
Larkin Feeney,
Mary Mooney
Ir J Psych Med September 2006;Vol
23 No 3: 100-102
A Randomized
Controlled Trial of a Smoking Cessation Intervention Among
People With a Psychotic Disorder
Amanda Baker, Robyn Richmond, Melanie Haile,
Terry J. Lewin, Vaughan J. Carr, Rachel L. Taylor,
Sylvia Jansons, and Kay Wilhelm
American
Journal of Psychiatry 163:1934-1942, November 2006
Reduced Thalamic
Volume in Patients With Chronic Schizophrenia After
Switching From Typical Antipsychotic Medications to Olanzapine
Babak Khorram, Donna J. Lang, Lili C. Kopala,
Robert A. Vandorpe, Qing Rui, Vina M. Goghari, Geoffrey N. Smith, and William
G. Honer
American
Journal of Psychiatry 163:2005-2007, November 2006
One-Year Stability
of Diagnosis in First-Episode Nonaffective Psychosis:
Influence of Sex
Ana Cristina Chaves, Jean Addington, Mary Seeman, Donald Addington
Can J Psychiatry 2006;51:711–714
Serum
Monitoring of Antipsychotic Drug Levels During Concomitant
Administration of Sertraline and Antipsychotic
Medication
Kathleen Pierson, Donald Addington, Jean Addington, Scott Patten
Can J Psychiatry 2006;51:715–718
Weight gain management in patients with
schizophrenia during treatment with olanzapine in
association with nizatidine
ASSUNCAO, Sheila
Seleri Marques, RUSCHEL, Sandra Inês, ROSA, Lucena de Cássia Rodrigues et al.
Rev. Bras. Psiquiatr., 2006, 1516-4446
Comparative
effectiveness of second-generation antipsychotics and
haloperidol in acute schizophrenia
ROBERT E. McCUE, RUBINA WAHEED, LEONEL URCUYO,
GERALDINE ORENDAIN, MICHEL D. JOSEPH, RICHARD CHARLES, and SYED M. HASAN
The British Journal of Psychiatry (2006) 189:
433-440
Modafinil and unconstrained motor activity in
schizophrenia. Double-blind crossover
placebo-controlled trial
TOM F. D. FARROW, MICHAEL D. HUNTER, ROZANA HAQUE, SEAN A. SPENCE
The British Journal of Psychiatry (2006) 189:
461-463
Understanding and Improving Treatment Adherence in Patients with Psychotic
Disorders: A Review and a Proposed Intervention
Staring, Anton
B.P.; Mulder, Cornelis L; van der Gaag, Mark; Selten,
Jean-Paul; Loonen, Anton J.M.; Hengeveld, Michiel W
Current Psychiatry Reviews, Volume 2, Number 4,
November 2006, pp. 487-494(8)
Experts Say Tread
Slowly When Trying to Interpret Study Results
Jim Rosack
Psychiatr News November 3, 2006. Volume 41, Number 21, page 23
Treatment adherence among patients with
schizophrenia treated with atypical and typical antipsychotics
Frank D. Gianfrancesco, Krithika Rajagopalan, Martha Sajatovic and
Ruey-hua Wang
Psychiatry Research. Volume 144, Issues 2-3, 15 November 2006, Pages 177-189
Relationship between obsessive–compulsive
symptoms and smoking habits amongst schizophrenic patients
Peter Dome, Zsofia Teleki,
Psychiatry Research. Volume 144, Issues 2-3, 15 November 2006, Pages 227-231
Avoiding EPS is key to realizing ‘atypical’ benefits
Curr Psychiatry. Vol. 5, No. 11 / November 2006
Paliperidone
Curr Psychiatry. Vol. 5, No. 11 / November 2006
Adverse Effects of Risperidone
on Spatial Working Memory in First-Episode Schizophrenia
James L. Reilly, Margret S. H. Harris, Matcheri S. Keshavan, John A.
Sweeney
Arch Gen Psychiatry. 2006;63:1189-1197
Prolonged
duration of untreated psychosis in nonaffective
first-episode psychotic disorders compared to other psychoses
Michael T. Compton, Joyce C. West, Mark Olfson
Symptom control,
functioning, and hospitalization status in French patients changed from oral
atypical antipsychotics to risperidone
long-acting injectable
Pierre-Michel Llorca,
Jean-Pierre Kahn, Véronique Moreau-Mallet, Philippe Bouhours, the French StoRMi
investigators group
Cost-effectiveness
of different clinical interventions for reducing the burden of schizophrenia in
Spain
Gutierrez-Recacha P, Chisholm D, Haro JM,
Salvador-Carulla L, Ayuso-Mateos
JL.
Acta Psychiatrica Scandinavica. Volume 114 Page 29 - December 2006
Coadministration
benzodiazepine and antidepressant drugs : the
state of art
P. Martin
L’Encephale.
Vol 32 - N° 5-C1 - Octobre 2006 : 753 - 766
Prediction of
Remission as a Combination of Symptomatic and Functional Remission and Adequate
Subjective Well-Being in 2960 Patients With
Schizophrenia
Martin Lambert, Benno
G. Schimmelmann, Dieter Naber,
Alexander Schacht, Anne Karow, Thomas Wagner, and Joerg Czekalla
J Clin Psychiatry 2006;67:1690-1697
Remission in
First-Episode Psychosis: Predictor Variables and Symptom Improvement Patterns
Robin Emsley, Piet P. Oosthuizen, Martin Kidd, Liezl Koen, Dana J. H. Niehaus, and H. Jadri Turner
J Clin Psychiatry 2006;67:1707-1712
Pharmacological treatment of primary
negative symptoms in schizophrenia: A systematic review
Brendan P. Murphy,
Young-Chul Chung,
Schizophrenia Research. Volume 88, Issues 1-3, December 2006, Pages 5-25
A model of anticholinergic
activity of atypical antipsychotic medications
Marci L. Chew,
Benoit H. Mulsant, Bruce G. Pollock, Mark E. Lehman,
Andrew Greenspan, Margaret A. Kirshner, Robert R. Bies, Shitij Kapur
and Georges Gharabawi
Schizophrenia Research. Volume 88, Issues 1-3, December 2006, Pages 63-72
Beneficial effects of ondansetron
as an adjunct to haloperidol for chronic, treatment-resistant schizophrenia: A
double-blind, randomized, placebo-controlled study
Zhang-Jin Zhang,
Wan-Hu Kang, Qiang Li, Xue-Yi Wang, Shao-Min
Schizophrenia Research. Volume 88, Issues 1-3, December 2006, Pages 102-110
The selective effect of antipsychotics
on the different dimensions of the experience of psychosis in schizophrenia
spectrum disorders
Romina Mizrahi, Michael Kiang, David C. Mamo,
Tamara Arenovich, R. Michael Bagby,
Robert B. Zipursky and Shitij
Kapur
Schizophrenia Research. Volume 88, Issues 1-3, December 2006, Pages 111-118
Reduced serum BDNF levels in schizophrenic
patients on clozapine or typical antipsychotics
Rodrigo W. Grillo, Gustavo L. Ottoni, Renata Leke, Diogo
O. Souza, Luiz V. Portela
and Diogo R. Lara
Journal of Psychiatric Research. Volume 41, Issues 1-2, January-February 2007, Pages 31-35
Violence and
Mental Illness — How Strong is the Link?
Richard A.
Friedman
Optimizing Early Prediction
for Antipsychotic Response in Schizophrenia
Chang,
Yue-Cune; Lane, Hsien-Yuan;
Yang, Kung-Han; Huang, Chieh-Liang
Journal of Clinical Psychopharmacology. 26(6):554-559, December 2006
Predictors of Neuroleptic-induced Dyskinesia
and Parkinsonism: The Influence of Measurement Methods and Definitions
Dean,
Charles E; Kuskowski, Michael A; Caligiuri,
Michael P
Journal of Clinical
Psychopharmacology. 26(6):560-565,
December 2006
Remission and Relapse in
the Outpatient Care of Schizophrenia: Three-year Results From the Schizophrenia
Outpatient Health Outcomes Study
Haro,
Josep Maria; Novick, Diego;
Suarez, David; Alonso, Jordi; Lepine,
Jean Pierre; Ratcliffe, Mark; and the SOHO Study
Group
Journal of Clinical
Psychopharmacology. 26(6):571-578,
December 2006
Priapism Associated With the Switch
From Oral to Injectable Risperidone
Kirshner,
Alla; Davis, Robert R
Journal of Clinical
Psychopharmacology. 26(6):626-628,
December 2006
The Relationship Between Prolactin Levels and
Glucose Homeostasis in Antipsychotic-treated Schizophrenic Patients
Howes,
Oliver D; Smith, Shubulade; Gaughran,
Fiona P; Amiel, Stephanie A; Murray, Robin M; Pilowsky, Lyn S
Journal of Clinical
Psychopharmacology. 26(6):629-631,
December 2006
Differential Rates of
Treatment Discontinuation in Clinical Trials as a Measure of Treatment
Effectiveness for Olanzapine and Comparator Atypical Antipsychotics for Schizophrenia
Kinon, Bruce J; Liu-Seifert, Hong; Adams, David H;
Citrome, Leslie
Journal of Clinical
Psychopharmacology. 26(6):632-637,
December 2006
Enhanced
Sensitivity to the Euphoric Effects of Alcohol in Schizophrenia
Deepak C D'Souza, Roberto B Gil, Steven Madonick, Edward B Perry, Kimberlee Forselius-Bielen, Gabriel Braley,
Lia Donahue, Tahir Tellioglu, Zoran Zimolo, Ralitza Gueorguieva and John H Krystal
Neuropsychopharmacology (2006) 31, 2767–2775
Effectiveness of long-term aripiprazole
therapy in patients with acutely relapsing or chronic, stable schizophrenia: a
52-week, open-label comparison with olanzapine
Wlodzimierz K. Chrzanowski, Ronald N. Marcus, Anne Torbeyns,
Margaretta Nyilas and
Robert D. McQuade
Psychopharmacology. Volume 189, Number 2 /
December, 2006: 259-266
Characteristics of early
psychosis
Patricia F. Schothorst,
Claudia Emck, Herman van Engeland
Compr Psychiatry. Volume 47, Issue
6, Pages 438-442 (November
2006)
The Prevalence of the Metabolic Syndrome in Psychiatric Inpatients With Primary Psychotic and Mood Disorders
Richard A. Bermudes,
Paul E. Keck, Jr., and Jeffrey A. Welge
Psychosomatics
47:491-497, December 2006
The effect of
variable cigarette consumption on the interaction with clozapine
and olanzapine
Haslemo T, Eikeseth PH,
Tanum L, Molden E, Refsum H
Eur J Clin Pharmacol. 2006 Dec;62(12):1049-1053. Epub 2006 Nov 7
Cognitive dysfunctions in
schizophrenia: potential benefits of cholinesterase inhibitor adjunctive
therapy
Florian Ferreri, Catherine Agbokou, Serge
Gauthier,
J Psychiatry Neurosci 2006;31(6):369-76
Occupancy of dopamine D(1), D (2) and
serotonin (2A) receptors in schizophrenic patients treated with flupentixol in comparison with risperidone
and haloperidol
Reimold M, Solbach C, Noda S, Schaefer JE, Bartels M, Beneke M, Machulla HJ, Bares R, Glaser T, Wormstall H
Psychopharmacology
(Berl). 2006 Nov 17; [Epub ahead of print]
A double-blind randomised
comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with
schizophrenia and comorbid depression
Vanelle JM, Douki S
Eur Psychiatry. 2006 Nov 17; [Epub
ahead of print]
Efficacy of amisulpride
in treating primary negative symptoms in first-episode psychosis: a pilot study
Brendan P. Murphy, Antonia H. Stuart, Darryl
Wade, Sue Cotton, Patrick D. McGorry
Human
Psychopharmacology: Clinical and Experimental. Volume 21,
Issue 8, Pages 511 - 517
Prolactin elevation of the antipsychotic risperidone is predominantly related to its 9-hydroxy
metabolite
Kristina I. Melkersson
Human
Psychopharmacology: Clinical and Experimental. Published
Online: 9 Nov
2006
Initial Treatment of
Severe Acute Psychosis with Fast Orally Disintegrating Risperidone Tablets
Normann C, Schmauss
M, Bakri N, Gerwe M, Schreiner A
Pharmacopsychiatry. 2006 Nov;39(6):209-212
Increased dyslipidemia in schizophrenic
outpatients using new generation antipsychotics
LEITAO-AZEVEDO,
Carmen Lúcia, GUIMARAES, Lísia Rejane, ABREU, Martha Guerra Belmonte de et al.
Rev. Bras. Psiquiatr., 2006, ahead of print
Diretrizes da Federação
Mundial das Sociedades de Psiquiatria Biológica para o Tratamento Biológico da
Esquizofrenia. Parte 1: Tratamento agudo
Peter Falkai, Thomas Wobrock,
Jeffrey Lieberman,
Birte Glenthoj, Wagner F. Gattaz, Hans-Jürgen Möller,
Força-Tarefa da WFSBP
para Diretrizes para o tratamento
biológico da esquizofrenia
Rev Psiq Clinica. Vol 33 - s 1 – 2006
Diretrizes da Federação
Mundial das Sociedades de Psiquiatria Biológica para
o Tratamento Biológico da Esquizofrenia. Parte 2: Tratamento de longo prazo
Peter Falkai, Thomas Wobrock,
Jeffrey Lieberman,
Birte Glenthoj, Wagner F. Gattaz, Hans-Jürgen Möller,
Força-Tarefa da WFSBP
para Diretrizes para o tratamento
biológico da esquizofrenia